Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | IGF1R | P08069 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CCR2 | P41597 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475769 | 0.95 | KDM4E (0.70) | KDM4EIGF1RHTTALDH1A1LMNA | |
| SCHEMBL4478168 | 0.95 | KDM4E (0.70) | KDM4EIGF1RHTTALDH1A1LMNA | |
| SCHEMBL4483824 | 0.95 | KDM4E (0.70) | KDM4EIGF1RHTTALDH1A1LMNA | |
| SCHEMBL297782 | 0.88 | IGF1R (0.73) | KDM4EIGF1RALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL11726331 | 0.88 | IGF1R (0.73) | KDM4EIGF1RALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL5626457 | 0.83 | ALDH1A1 (0.74) | KDM4EALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4465545 | 0.83 | KDM4E (1.00) | KDM4EIGF1RHTTLMNAADRB2 | |
| SCHEMBL4468044 | 0.83 | KDM4E (1.00) | KDM4EIGF1RHTTLMNAADRB2 | |
| SCHEMBL4478754 | 0.83 | KDM4E (1.00) | KDM4EIGF1RHTTLMNAADRB2 | |
| Hydrochloric Acid SCHEMBL4466480 | 0.82 | KDM4E (0.97) | KDM4EIGF1RHTTLMNAADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576086-B2 | N1-benzyl-N4-(phenylpropane-2-yl-3-ol)piperazine; triple action on hydroxytryptamine (5-HT), noradrenalin (NA)and dopamine(DA); on brain synapses; cytochrome P-450 monooxygenase enzyme system antagonists; enzyme inhibitors; side effect reduction | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2009-08-18 | — | — | US | claimed |
| US-20050267121-A1 | Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2005-12-01 | — | — | US | claimed |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
| US-7576086-B2 | N1-benzyl-N4-(phenylpropane-2-yl-3-ol)piperazine; triple action on hydroxytryptamine (5-HT), noradrenalin (NA)and dopamine(DA); on brain synapses; cytochrome P-450 monooxygenase enzyme system antagonists; enzyme inhibitors; side effect reduction | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2009-08-18 | — | — | US | disclosed |
| US-20050267121-A1 | Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | KDM4E 1755/4885IGF1R 3565/4885HTT 3738/4885 |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | KDM4E 1755/4885IGF1R 3565/4885HTT 3738/4885 |
| US-20050267121-A1 | Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant | AANAT, GAP43, TPH2 | KDM4E 2865/4885IGF1R 3820/4885HTT 1379/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | KDM4E 1755/4885IGF1R 3565/4885HTT 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.